Indication

As monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (HER2+) breast cancer who have received two or more prior anti-HER2-based regimens.

Medicine details

Medicine name:
trastuzumab deruxtecan (Enhertu)
SMC ID:
SMC2388
Pharmaceutical company
Daiichi Sankyo UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
17 January 2022
SMC meeting date:
07 December 2021
Patient group submission deadline:
06 September 2021